New drug duo aims to control rare blood cancer
NCT ID NCT03697512
Summary
This study is testing the safety and effectiveness of combining two existing drugs, ibrutinib and rituximab, for people newly diagnosed with a slow-growing blood cancer called marginal zone lymphoma. The trial will enroll 175 adults who have not yet received any chemotherapy or immunotherapy for their cancer. Researchers want to see if this combination can help patients achieve a complete response and live longer without their cancer progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O. Spedali Civili di Brescia
Brescia, 25123, Italy
-
A.O.U. Città della Salute e della Scienza di Torino Ospedale Molinette
Torino, TO, 10126, Italy
-
AAST Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
-
Azienda Ospedaliera Arcispedale Santa Maria Nuova IRCCS
Reggio Emilia, 42123, Italy
-
Azienda Ospedaliera Universitaria Ospedali Riuniti - Università Politecnica delle Marche
Ancona, 60100, Italy
-
Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)
Trieste, Italy
-
CHRU de Strasbourg
Strasbourg, 67091, France
-
CHU Dijon Bourgogne - Hôpital François Mitterand
Dijon, 21000, France
-
CHU UCL Namur / site Godinne
Yvoir, B5530, Belgium
-
CHU d'Estaing
Clermont-Ferrand, Cedex 1, 63003, France
-
CHU de Grenoble - Hôpital Albert MICHALLON
La Tronche, 38700, France
-
CHU de Montpellier
Montpellier, Cedex 05, 34295, France
-
CHU de Nancy - Hôpital Brabois
Vandœuvre-lès-Nancy, 54500, France
-
CHU de Rennes Pontchaillou
Rennes, Cedex 9, 35033, France
-
CHU de Tours - Hôpital Bretonneau
Tours, Cedex 01, 37004, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Fondazione IRCCS - Cà Granda - Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Fondazione IRCCS - Policlinico San Matteo
Pavia, 27100, Italy
-
Giovanni Paolo II/I.R.C.C.S. Istituto Tumori
Bari, 70124, Italy
-
Hôpitaux Universitaires de Genève
Geneva, 1211, Switzerland
-
IHBN - CHU Côte de Nacre
Caen, 14033, France
-
IUCT Oncopole Toulouse
Toulouse, 31100, France
-
Inselspital Bern
Bern, 3010, Switzerland
-
Institut Bergonié
Bordeaux, 33076, France
-
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.
Lisbon, 1099-023, Portugal
-
Istituto Oncologico della Svizzera Italiana (IOSI)
Bellinzona, Canton Ticino, 6500, Switzerland
-
Kantonalspital Baden
Baden, 5404, Switzerland
-
Ospedale Oncologico Businco
Cagliari, 09121, Italy
-
Ospedale San Raffaele
Milan, MI, 20132, Italy
-
Ospedale degli Infermi
Ponderano, BI, 13875, Italy
-
Ospedale di Circolo e Fondazione Macchi di Varese
Varese, 21100, Italy
-
Saint Louis Hospital
Paris, 75010, France
-
U.O. Ematologia AUSL Ravenna
Ravenna, 48121, Italy
-
Università degli Studi di Roma La Sapienza
Roma, 00185, Italy
-
Universitätsspital Zürich
Zurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.